A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed light beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

A treatment method is disclosed capable of reducing the burden on a patient and enhancing the effect of killing tumor cells. A treatment method for killing a tumor cell, the method including inserting a catheter into a main artery of an organ having the tumor cell, administering an antibody-photosensitive substance into a vein before the inserting of the catheter, inserting an optical fiber into the catheter, reducing an influence of blood in the artery on a near-infrared ray, irradiating at least one of a tumor, the vicinity of the tumor, or a regional lymph node with a first near-infrared ray by the optical fiber, and irradiating an antibody-photosensitive substance bound to a tumor cell membrane in the tumor cell with a second near-infrared ray having a shorter wavelength than that of the first near-infrared ray.

A method of treating a subject suffering from, or susceptible to, a condition that can be ameliorated by inhalation of gaseous nitrite comprises the use of an apparatus comprising an activating unit that includes a photosensitiser excitable by absorption of light to excite oxygen to a singlet state, and a light source arranged to illuminate the photosensitiser. Air is caused to flow through the activating unit while the photosensitiser is illuminated by the light source, and after passing through the activating unit, is directed to the respiratory tract of the subject.

Methods and apparatuses for immunosuppression and/or immunomodulation for the treatment of an improper immune response with the use of UV light. In particular, described herein are methods and apparatuses for the treatment of inflammatory disorders using UVB light at appropriate intensities, durations and (internal) body regions in order to effect substantial and reliably treatment.

A system and method can be used to denervate at least a portion of a bronchial tree. An energy emitter of an instrument is percutaneously delivered to a treatment site and outputs energy to damage nerve tissue of the bronchial tree. The denervation procedure can be performed without damaging non-targeted tissue. Minimally invasive methods can be used to open airways to improve lung function in subjects with COPD, asthma, or the like. Different sections of the bronchial tree can be denervated while leaving airways intact to reduce recovery times.

A light-emitting, antimicrobial tuber, instrument or catheter includes a thin, flexible tube having an optically transparent wall; and a light transmitter configured and arranged to emit light through the tube, which may be ultraviolet C (UVC) irradiation, photodynamic therapy (PDT), violet-blue light therapy, and other light-based therapies. In one embodiment, violet-blue light from 400-500 nm in wavelength, such as 405 nm, for instance, is used. The device is used on a patient and a therapeutic amount of light is administered to the patient, thereby reducing the risk of infections being transmitted from the instrument, tube or catheter to the patient, generally. The device may be configured for use in the urinary tract or as intravascular, and may be indwelling or temporary. Light may be administered for the duration of use or another time period effective to halt, inhibit, or reduce microbial or fungal growth.

Provided herein are methods and compositions for treating, mitigating, or preventing Parkinson's disease by administration of an anti-malassezial agent wherein the anti-malassezial agent is oteseconazole, tavaborole or 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol.

A method for heat treating biological tissues includes providing a pulsed energy source having energy parameters selected so as to raise a target temperature to a level to achieve a therapeutic effect, while the average temperature rise of the tissue over a prolonged period of time is maintained at or below a predetermined level so as not to permanently damage the target tissue. Application of the pulsed energy source to the target tissue induces a heat shock response and stimulates heat shock protein activation in the target tissue so as to therapeutically treat the target tissue.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

Systems, methods, and computer-readable media for enabling ultraviolet radiation treatments are provided.